You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Dow
Moodys
Colorcon

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Litigation Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Docket   Start Trial Date Filed 2015-04-27
Court District Court, S.D. New York Date Terminated
Cause 15:1 Antitrust Litigation (Monopolizing Trade) Assigned To Ronnie Abrams
Jury Demand Plaintiff Referred To
Parties ACTAVIS PLC; AMERICAN SALES COMPANY, LLC; CESAR CASTILLO, INC.; MYLAN PHARMACEUTICALS, INC.; MYLAN, INC.; RANBAXY LABORATORIES LTD.; RANBAXY PHARMACEUTICALS, INC.; RANBAXY, INC.; SUN PHARMACEUTICAL INDUSTRIES LTD.; TAKEDA AMERICA HOLDINGS, INC.; TAKEDA DEVELOPMENT CENTER AMERICAS, INC.; TAKEDA PHARMACEUTICAL CO. LTD.; TAKEDA PHARMACEUTICALS U.S.A., INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; WATSON LABORATORIES, INC.
Patents 6,166,043; 6,172,090; 6,329,404
Attorneys Adam R Lawton; Bradley J. Demuth; David S. Nalven; Gregory L. Skidmore; Gregory Thomas Arnold; John O'Quinn; Karen Hoffman Lent; Kristen Anne Johnson; Linda P. Nussbaum; Ross Lee Weiner; Stacey Anne Mahoney; Steven Craig Sunshine; Thane D. Scott; Thomas Matthew Sobol
Firms Hagens Berman Sobol Shapiro LLP; Hagens Berman Sobol Shapiro LLP (MA); Kirkland & Ellis LLP - NYC; Kirkland and Ellis LLP (Washington); Morgan, Lewis and Bockius LLP (NY); Munger Tolles & Olson LLP; Nussbaum Law Group, P.C.; Skadden, Arps, Slate, Meagher & Flom LLP (DC)
Link to Docket External link to docket
Small Molecule Drugs cited in In Re: Actos Direct Purchaser Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-04-27 1 “’042 Patent”) December 26, 2000 June 19, 2016 6,166,043 (the “’043 Patent”) …its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug product patents claiming ACTOS only if the patents in fact External link to document
2016-01-07 54 “’042 Patent”) December 26, 2000 June 19, 2016 6,166,043 (the “’043 Patent”) …listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January External link to document
2016-01-28 62 medications: U.S. Patent Nos. 5,965,584 (“’584 patent”) and 6,329,404 (“’404 patent”), both of which …U.S. Patent No. 4,687,777 (“’777 patent”), which expired in January 2011. Id. ¶ 158. Two patents claim…traditional patent settlement, Teva (the alleged patent infringer) agreed to pay Takeda (the patent holder… the underlying patent infringement cases, or (2) the supposed weakness of the patent claims would have…relating to the ACTOS and ACTOplus met patent litigations and patent settlements are no different from those External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKinsey
Express Scripts
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.